Zai Lab (ZLAB) Change in Accured Expenses (2020 - 2026)
Zai Lab (ZLAB) posted quarterly Change in Accured Expenses of -$17.6 million for Q1 2026, up 24.22% year-on-year from -$14.2 million in Q1 2025, and down 253.12% on a QoQ basis from $11.5 million in Q4 2025.
Zai Lab (ZLAB) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Zai Lab (ZLAB) has reported Change in Accured Expenses for 7 consecutive years, with -$17.6 million the latest figure, recorded in Q1 2026.
- Quarterly Change in Accured Expenses rose 24.22% year-over-year to -$17.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.4 million (up 193.64% YoY) and the FY2025 annual result came in at $4.8 million, up 121.57% from the prior year.
- Change in Accured Expenses fell to -$17.6 million in Q1 2026 per ZLAB's latest filing, from $11.5 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for ZLAB reached as high as $19.6 million in Q4 2023 and fell as low as -$34.2 million in Q1 2024.
- A 5-year average of -$453411.8 and a median of $5.7 million in 2022 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 140.71% — and 2025, when it jumped 836.09%.
- Year by year, Change in Accured Expenses stood at $5.8 million in 2022, then jumped by 239.75% to $19.6 million in 2023, then decreased by 24.26% to $14.8 million in 2024, then retreated by 22.34% to $11.5 million in 2025, then tumbled by 253.12% to -$17.6 million in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$17.6 million, $11.5 million, and $9.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Zai Lab | 20.76 Bn | 20.01 Bn | 61.30 Mn | -17.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.64 Mn |
| Mar 31, 2026 | -17.64 Mn |
| Dec 31, 2025 | 11.52 Mn |
| Dec 31, 2025 | 11.52 Mn |
| Sep 30, 2025 | 9.18 Mn |
| Sep 30, 2025 | 9.18 Mn |
| Jun 30, 2025 | 7.33 Mn |
| Jun 30, 2025 | 7.33 Mn |
| Mar 31, 2025 | -23.28 Mn |
| Mar 31, 2025 | -23.28 Mn |
| Dec 31, 2024 | 14.83 Mn |
| Dec 31, 2024 | 14.83 Mn |
| Sep 30, 2024 | -1.25 Mn |
| Sep 30, 2024 | -1.25 Mn |
| Jun 30, 2024 | -1.40 Mn |
| Jun 30, 2024 | -1.40 Mn |
| Mar 31, 2024 | -34.20 Mn |
| Mar 31, 2024 | -34.20 Mn |
| Dec 31, 2023 | 19.58 Mn |
| Dec 31, 2023 | 19.58 Mn |